ABC.L Regulatory News (ABC)

ABCAM PLC

("Abcam" or "the Company")

Directors' dealings

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, has today been notified that on 8 October 2014, Jeff Iliffe, a Director of the Company, exercised nil cost share options over 10,000 Ordinary Shares of 0.2 pence each in the Company ("Ordinary Shares") and exercised 40,000 share options with an exercise price of 62.4 pence per share.

Following this transaction, Mr Iliffe's total interest in the Company has increased by 50,000 Ordinary Shares to a total of 326,000 Ordinary Shares, representing approximately 0.16% of the Company's issued share capital.

For further information please contact:

Notes for editors:

About Abcam plc

Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices enabling local services, multi-language support sells to over 100 countries. The Company was founded in 1998, and now employs over 740 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com